Although a lot is known about how castration-resistant prostate cancers become refractory to second-generation androgen receptor antagonists, the mechanism behind resistance to CYP17 inhibitors remains a mystery. An alternative androgen synthesis pathway identified by a team from the Cleveland Clinic may change the game.